Paratek Stock Is Trading Higher As CDC Adds Nuzyra As Recommended Antibiotic For Plague Treatment

The Center for Disease Control and Prevention (CDC) has added Paratek Pharmaceuticals Inc's PRTK antibiotic Nuzyra (omadacycline) as an alternative agent for pre-exposure prophylaxis and postexposure prophylaxis of primary bubonic and pharyngeal plague infections in adults 18 years of age and over.
According to the CDC, Yersinia pestis (Y. pestis), the bacterium that causes plague, is recognized as a potential bioterrorism weapon.
In 2016 Paratek, through a cooperative effort with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), conducted a research study of Nuzyra against pathogenic agents.
Nuzyra is a once-daily oral and intravenous antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Price Action: PRTK shares are up 13.4% at $6.16 during the premarket session on the last check Thursday.